The UK and US have finalized a landmark trade agreement that will keep zero import taxes on British medicine products going into the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the NHS. This commitment ensures that import taxes on these key products will be held at zero for a timeframe of three years.
This agreement comes after previous warnings to dramatically increase duties on branded pharmaceutical imports, with figures discussed as high as 100%.
"This agreement between the UK bolsters the international landscape for innovative medicines and brings long-overdue balance to transatlantic drug exports," a release declared.
Economic Significance
Pharmaceuticals are one of the Britain's most significant exports to the America, which is by far the largest destination for leading UK drugmakers.
Trade data show that in the one-year period prior to September, the UK sold medicines valued at over eleven billion pounds to the US. This amount represented a significant portion of all goods exports in that period.
"This deal safeguards work, stimulates investment and sets the stage for the UK to establish itself as a international leader for medical research," a minister commented.
Detailed NHS Changes
The pact includes several specific commitments from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise total public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Last year, refunds topped twenty percent.
Broader Context
This agreement comes amid a protracted dispute between the drug companies and the British authorities over drug pricing and approval rates.
This friction were exacerbated by assertions that US customers were charged a premium for the identical medicines than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
